9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Cancer

Estimated Enrollment: 40

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Progression-free survival of the participants(PFS),  Overall survival of the participants(OS),  Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Safety (adverse events)

Interventions: Anti-PD-1 antibody, DC-CIK Immunotherapy

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2020

Completion Date: December 2020

Last  Posted Date: April 16, 2019

Location: Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital, Beijing, China

Website Link: https://ClinicalTrials.gov/show/NCT03393858

Was this article helpful?
Dislike 0